All In Biotech

Drug Trial Radar · NCT06841679

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

A Multi-national, Open-label, Randomized Phase II/III Clinical Study of Utidelone Capsule (UTD2) Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 778 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

778

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Sep 1, 2030

Study completion Sep 1, 2030

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.

Conditions

  • Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • Utidelone CapsuleDrug

    UTD2 40 mg/m2/d, po, qd, day 1-5, q3w

  • Utidelone CapsuleDrug

    50 mg/m2/d, po, qd, day 1-5, q3w

  • Utidelone CapsuleDrug

    60 mg/m2/d, po, qd, day 1-5, q3w

  • Fluoropyrimidine- and Platinum-containing TherapyDrug

    CAPOX: Capecitabine 1700 mg/m2/d, po, bid, d1-14,q3w, Oxaliplatin 130 mg/m2, iv, d1, q3w. After completing 6 times (18 weeks) of oxaliplatin treatment, the investigator may decide whether to continue oxaliplatin treatment for up to 8 times (24 weeks) based on the participant's benefits and safety. FOLFOX: Oxaliplatin 85 mg/m2, iv, d1, q2w. Folinic Acid 400 mg/m2, iv, d1, q2w, 5-FU 400 mg/m2 IV bolus d1 then 5-FU 2400 mg/m2 IV infusion over 46 to 48 hours, q2w. After completing 9 times (18 weeks) of treatment with oxaliplatin combined with folinic acid and 5-FU, the investigator may decide whether to continue FOLFOX treatment for up to 12 times (24 weeks) based on the participant's benefits and safety.

  • OxaliplatinDrug

    130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles

  • Utidelone CapsuleDrug

    UTD2 po, on d1-5, q3w (dose decided after the phase II)

  • PD-1 inhibitorDrug

    Whether to combine a PD-1 inhibitor will depend on the locally approved indications for the PD-1 inhibitor. If the participant's condition meets the locally approved indications for PD-1 inhibitors, the investigator may determine, in accordance with clinical guidelines, that the participant is eligible to receive treatment with UTD2 combined with fluoropyrimidine- and platinum-containing therapy, with or without a PD-1 inhibitor. If a PD-1 inhibitor is administered in combination, tislelizumab (200 mg), or pembrolizumab (200 mg), or nivolumab (360 mg), iv, day1, q3w. Alternatively, the investigator may select the dosage and administration cycle of other locally approved PD-1 inhibitors in accordance with the locally approved package inserts. The PD-1 inhibitor will be given up to 2 years.

  • CapecitabineDrug

    Capecitabine 1700 mg/m2/d po, bid, d1-14,q3w

  • CapecitabineDrug

    Capecitabine, 2000 mg/m2/d, po, bid, d1-14, q3w

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of UTD2 and capecitabine in combination with oxaliplatin in Phase IITime frame: From Day 1 to Day 21
  2. Overall Survival (OS)Time frame: 12 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Bioresearch Partner

    Hialeah, Florida · Not yet recruiting

  • AnYang Tumor Hospital

    Anyang, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Jinan Municipal Central Hospital

    Jinan, China · Recruiting

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.